About
As part of the Life Sciences team at Hanson Wade, I am responsible for creating niche &…
Activity
-
Newly Released Agenda 🔔 In today’s rapidly evolving biopharmaceutical industry, environmental, health, and safety (EHS) leaders face increasingly…
Newly Released Agenda 🔔 In today’s rapidly evolving biopharmaceutical industry, environmental, health, and safety (EHS) leaders face increasingly…
Liked by Ellie Rapps
-
📣Your 2025 Q1 World CNS Series Dates Have Been Released!📣 📅 Mark your calendars: 𝟮𝗻𝗱 𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗲𝗴𝗿𝗮𝗱𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗖𝗡𝗦…
📣Your 2025 Q1 World CNS Series Dates Have Been Released!📣 📅 Mark your calendars: 𝟮𝗻𝗱 𝗣𝗿𝗼𝘁𝗲𝗶𝗻 𝗗𝗲𝗴𝗿𝗮𝗱𝗮𝘁𝗶𝗼𝗻 𝗳𝗼𝗿 𝗖𝗡𝗦…
Liked by Ellie Rapps
Experience
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Education
-
-
-
A Levels in Biology, Mathematics and History
Volunteer Experience
-
Biosoc Parent
Biological Sciences Society University of Southampton
- Present 4 years
Education
-
Treasurer
Glen Eyre Netball
- 10 months
-
Fitness Secretary
Glen Eyre Netball
- Present 3 years 3 months
-
Volunteer in Musoma, Tanzania
Make A Difference in Tanzania
- Present 6 years 3 months
Honors & Awards
-
Explore Learning Recognition Award
Explore Learning
More activity by Ellie
-
The FDA’s verdict on Lykos Therapeutics’ MDMA-assisted therapy for PTSD, whilst negative news, offers invaluable lessons, highlighting the need for…
The FDA’s verdict on Lykos Therapeutics’ MDMA-assisted therapy for PTSD, whilst negative news, offers invaluable lessons, highlighting the need for…
Shared by Ellie Rapps
-
Couple of pictures from last months mRNA Based Therapeutics Summit in Boston, MA. Being the Partner Operations Manager was no small feat with 47…
Couple of pictures from last months mRNA Based Therapeutics Summit in Boston, MA. Being the Partner Operations Manager was no small feat with 47…
Liked by Ellie Rapps
-
In case you missed it, Coya announced last week the filing of new U.S. patents for COYA 301 in combination with GLP-1. The combination presents a…
In case you missed it, Coya announced last week the filing of new U.S. patents for COYA 301 in combination with GLP-1. The combination presents a…
Liked by Ellie Rapps
-
A phase 1a trial of healthy volunteers showed that treatment with investigational PMN310 was safe and well tolerated across 4 dose levels, with…
A phase 1a trial of healthy volunteers showed that treatment with investigational PMN310 was safe and well tolerated across 4 dose levels, with…
Liked by Ellie Rapps
-
New data from a phase 2b/3 study of patients with early-stage #AD showed that treatment with blarcamesine was safe, with no associated neuroimaging…
New data from a phase 2b/3 study of patients with early-stage #AD showed that treatment with blarcamesine was safe, with no associated neuroimaging…
Liked by Ellie Rapps
-
The proof-of-concept SHINE study assessing CT1812 in #AD achieved its primary objective and demonstrated a favorable safety and tolerability profile,…
The proof-of-concept SHINE study assessing CT1812 in #AD achieved its primary objective and demonstrated a favorable safety and tolerability profile,…
Liked by Ellie Rapps
-
Coya Therapeutics has been selected as a finalist for the Biotech Innovation Award by Biotech Week Boston! Check out the rest of the finalists for…
Coya Therapeutics has been selected as a finalist for the Biotech Innovation Award by Biotech Week Boston! Check out the rest of the finalists for…
Liked by Ellie Rapps
-
ICYMI: The FDA granted fast track designation to AC Immune's anti-ptau immunotherapy candidate JNJ-2056, formerly known as ACI-35.030, in development…
ICYMI: The FDA granted fast track designation to AC Immune's anti-ptau immunotherapy candidate JNJ-2056, formerly known as ACI-35.030, in development…
Liked by Ellie Rapps
-
Thrilled to announce this agreement today! Excited to see our novel BBB-penetrant capsid and potent zinc finger repressors moving forward in the…
Thrilled to announce this agreement today! Excited to see our novel BBB-penetrant capsid and potent zinc finger repressors moving forward in the…
Liked by Ellie Rapps
-
Perfectly timed for the release of the 6th CNS Drug Delivery Summit this week! John L. McGuire will be sharing Alcyone Therapeutics Inc.’s story of…
Perfectly timed for the release of the 6th CNS Drug Delivery Summit this week! John L. McGuire will be sharing Alcyone Therapeutics Inc.’s story of…
Shared by Ellie Rapps
-
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for…
Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for…
Liked by Ellie Rapps
Other similar profiles
Explore collaborative articles
We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.
Explore More